Cite
DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.
MLA
Wang, Chuan, et al. “DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.” Frontiers in Immunology, vol. 12, Oct. 2021, pp. 1–15. EBSCOhost, https://doi.org/10.3389/fimmu.2021.763086.
APA
Wang, C., Zainal, N. S., Chai, S. J., Dickie, J., Gan, C. P., Zulaziz, N., Lye, B. K. W., Sutavani, R. V., Ottensmeier, C. H., King, E. V., Abraham, M. T., Ismail, S. M. binti, Lau, S. H., Kallarakkal, T. G., Mun, K. S., Zain, R. binti, Abdul Rahman, Z. A., Thomas, G. J., Cheong, S. C., & Savelyeva, N. (2021). DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. Frontiers in Immunology, 12, 1–15. https://doi.org/10.3389/fimmu.2021.763086
Chicago
Wang, Chuan, Nur Syafinaz Zainal, San Jiun Chai, James Dickie, Chai Phei Gan, Natasha Zulaziz, Bryan Kit Weng Lye, et al. 2021. “DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.” Frontiers in Immunology 12 (October): 1–15. doi:10.3389/fimmu.2021.763086.